Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Operating Expenses (2016 - 2025)

Ptc Therapeutics has reported Operating Expenses over the past 14 years, most recently at $236.0 million for Q4 2025.

  • Quarterly results put Operating Expenses at $236.0 million for Q4 2025, down 37.15% from a year ago — trailing twelve months through Dec 2025 was $863.7 million (down 22.14% YoY), and the annual figure for FY2025 was $863.7 million, down 22.14%.
  • Operating Expenses for Q4 2025 was $236.0 million at Ptc Therapeutics, up from $208.0 million in the prior quarter.
  • Over the last five years, Operating Expenses for PTCT hit a ceiling of $423.4 million in Q2 2023 and a floor of $205.9 million in Q1 2025.
  • Median Operating Expenses over the past 5 years was $250.6 million (2021), compared with a mean of $270.5 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 64.16% in 2023 and later tumbled 46.4% in 2024.
  • Ptc Therapeutics' Operating Expenses stood at $250.0 million in 2021, then soared by 47.13% to $367.8 million in 2022, then dropped by 18.09% to $301.2 million in 2023, then increased by 24.67% to $375.6 million in 2024, then tumbled by 37.15% to $236.0 million in 2025.
  • The last three reported values for Operating Expenses were $236.0 million (Q4 2025), $208.0 million (Q3 2025), and $213.8 million (Q2 2025) per Business Quant data.